NIPS

Juno Diagnostics™ Announces Publication Describing New NIPS Methodology in the American Journal of Obstetrics & Gynecology (AJOG - "The Gray Journal")

Retrieved on: 
Monday, April 3, 2023
Parent, Prenatal care, Juno, NIPS, Entrepreneurship, American Journal, Data analysis, Obstetrics, Patient, AJOG, SAN, AC1, Medical device, Gynaecology

The Company's novel NIPS approach offers a convenient and affordable avenue to access prenatal care for providers and patients, including those located remotely or within medical deserts.

Key Points: 
  • The Company's novel NIPS approach offers a convenient and affordable avenue to access prenatal care for providers and patients, including those located remotely or within medical deserts.
  • According to the researchers, the Juno Hazel™ tests provide a promising solution to ensure all parents-to-be and families have an equal opportunity to access high-quality prenatal information on their own time and terms.
  • "Publication of these results in The American Journal of Obstetrics & Gynecology is an exciting achievement that further validates our mission to disrupt the current NIPS paradigm," said Dirk van den Boom , Founder and Chief Executive Officer of JunoDx™.
  • These are important findings that will significantly advance the field of NIPS testing and broaden access for more parents around the globe."

Bionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis

Retrieved on: 
Wednesday, March 15, 2023
DSM-IV codes, Fragile X syndrome, LDT, Epilepsy, NIPS, SAN, CGG, ASD, Genome, Chromosome, Spectrum, Patient, SVS, History, OGM, Intellectual disability, Child, FMR1, Medical imaging

SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV.

Key Points: 
  • SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV.
  • These LDTs offer a genome-wide assessment of structural variants (SVs) and provide comprehensive testing for most common and rare chromosomal abnormalities.
  • The reports from this LDT will include a whole genome analysis to assess for SVs of diagnostic and prognostic value.
  • “We are pleased to see the launch of Bionano Laboratories' LDTs for postnatal and prenatal analysis, which can assist patients in their diagnostic and prognostic journey.

JUNO DIAGNOSTICS™ EXPANDS ITS PRODUCT PORTFOLIO WITH THE LAUNCH OF JUNO HAZEL™ PLUS AND ANNOUNCES EARLY ACCESS PROGRAM (EAP) FOR INNOVATIVE NIPS TESTS

Retrieved on: 
Monday, January 9, 2023
Klinefelter syndrome, Turner syndrome, Blood, XYY syndrome, Commercial Operating System (COS), Prenatal care, Genetic testing, SAN, Phlebotomy, EAP, XXY, Pregnancy, Patient, Hazel, Edwards, Special access program, Physician, NIPT, XYY, NIPS, Trisomy, Down syndrome, Edwards syndrome, Genetic counseling, Juno, Pharmaceutical industry

Similar to the Juno Hazel™ screening test, Juno Hazel™ Plus leverages JunoDx's proprietary Sample Collection Kit to improve early access to high-quality genetic testing without the high costs, long lead times, and phlebotomy requirements of venous-based NIPS.

Key Points: 
  • Similar to the Juno Hazel™ screening test, Juno Hazel™ Plus leverages JunoDx's proprietary Sample Collection Kit to improve early access to high-quality genetic testing without the high costs, long lead times, and phlebotomy requirements of venous-based NIPS.
  • Juno Hazel™ Plus offers a comprehensive prenatal screening solution by screening for common chromosomal trisomies, sex chromosome aneuploidies, and fetal sex.
  • "The expansion of our product portfolio with the launch of our second NIPS test , Juno Hazel™ Plus, represents a significant milestone for JunoDx™.
  • To ensure every pregnancy has the opportunity to benefit from our product portfolio, the time is now to create and launch a formalized Early Access Program.

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

Retrieved on: 
Thursday, January 5, 2023
American College, Precision medicine, Medical genetics, ACMG, American College of Medical Genetics and Genomics, SALT, PPV, Myriad Genetics, DiGeorge syndrome, SCAS, Genetic testing, Prequel, MYGN, Chromosome, Patient, Guideline, Physician, Genetics, NIPS, Fetus, Association for Molecular Pathology v. Myriad Genetics, Inc., Genetic distance, Trisomy, Medical imaging, Genomics

Myriad Genetics’ Prequel NIPS already offers this screening for SCAs and common microdeletions, such as 22q, for physicians and patients who opt-in, providing a flexible option that is consistent with ACMG's recommendations.

Key Points: 
  • Myriad Genetics’ Prequel NIPS already offers this screening for SCAs and common microdeletions, such as 22q, for physicians and patients who opt-in, providing a flexible option that is consistent with ACMG's recommendations.
  • FirstGene is a 4-in-1 offering that includes NIPS for chromosomal abnormalities, carrier screening for recessive conditions, simultaneous single-gene assessment of whether the fetus is affected with a condition identified via carrier screening, and feto-maternal blood compatibility.
  • “We’re excited to introduce our FirstGene product in Q3 2023,” said Melissa Gonzales, President, Women’s Health, Myriad Genetics.
  • We are very encouraged to see that initial data supports our view that Prequel provides exemplary PPV for 22q screening via NIPS.”

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

Retrieved on: 
Monday, November 14, 2022
CNV, MYGN, LCGC, Cancer, Myriad Genetics, Sumathi Best Television Current Reporting Award, Risk, Health, CGC, Body mass index, Prenatal care, DNA, Chromosome, ASCP, HIV disease progression rates, Physician, Pregnancy, Emory University, Risk assessment, Genetic counseling, MS, Senior counsel, NSGC, JCO, Genetics, Myriad, TommyInnit, Breast cancer, Prequel, ESG, Cleveland Clinic, Precision medicine, Woman, CEU, Association for Molecular Pathology v. Myriad Genetics, Inc., SALT, Genetic testing, Patient, Genome, Agriculture, Pharmaceutical industry, Management, Medical imaging, NIPS

Were committed to increasing collaboration with the genetic counselor community to make genetic testing more accessible, affordable and easier to use for all patient populations.

Key Points: 
  • Were committed to increasing collaboration with the genetic counselor community to make genetic testing more accessible, affordable and easier to use for all patient populations.
  • Data will highlight how technological improvements now allow for the detection of copy number variants (CNVs) across the genome in NIPS.
  • Myriad Genetics will sponsor NSGCs welcome reception for all genetic counselors who are first-time conference attendees, Wednesday, Nov. 16, 6:00-7:00 p.m. CT.
  • Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all.

Non-invasive Prenatal Testing Global Market Report 2022: Favourable Reimbursement Scenario Boosts Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
Managed Care, Health, Other Health, Medical Devices, Blood, Marketing, University College London, Chromosome, Down syndrome, Health education, NIPT, Fetus, Opportunity, DNA, Trisomy, Attention, US, Insurance, Genetic counseling, Region, Application, NIPS, Growth, Pregnancy, COVID-19, Infection, Risk, Fudan University, Medical imaging, Health insurance

The "Non-invasive Prenatal Testing Market, by Test Type, by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis,2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-invasive Prenatal Testing Market, by Test Type, by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis,2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Noninvasive prenatal testing (NIPT) is also known as noninvasive prenatal screening (NIPS).
  • Obtaining reimbursement for tests from payers is expected to offer lucrative growth opportunities for players in the global non-invasive prenatal testing market.
  • Moreover, attention towards health education, subsidies for NIPT, and genetic counseling is also expected to aid in growth of the market.

JUNO DIAGNOSTICS ANNOUNCES PRESENTATION AT CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE

Retrieved on: 
Tuesday, October 25, 2022
Genetic testing, SAN, LinkedIn, CA, Phlebotomy, Patient, Company, NIPS, Collection, Credit, Conference, Medical device

SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Juno Diagnostics (JunoDx), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced participationin the Credit Suisse 31st Annual Healthcare Conference, being held on November 7-10, 2022, in Rancho Palos Verdes, CA.

Key Points: 
  • SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Juno Diagnostics (JunoDx), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced participationin the Credit Suisse 31st Annual Healthcare Conference, being held on November 7-10, 2022, in Rancho Palos Verdes, CA.
  • JunoDx executive management will present a company overview on Wednesday, November 9th at 12:50 pm PT and will host individual investor meetings the same day.
  • Juno Diagnostics is a category-defining health company bringing vital prenatal health information to patients by combining access, affordability, and transparency.
  • For more information, visit www.junodx.com and engage with us on LinkedIn.

Ambry’s New Reproductive Health Program Uses Digital Platform to Make It Easier for Patients to Access Genetic Screening Before and During Pregnancy

Retrieved on: 
Wednesday, October 19, 2022
Research, Hospitals, Baby, Maternity, Genetics, Fitness & Nutrition, Biotechnology, Health, Consumer, Science, Physician, Genetics, Genetic counseling, Education, Digital technology, American College of Medical Genetics and Genomics, Ashkenazi Jews, Disease, Risk, American College of Obstetricians and Gynecologists, Trisomie 21, Woman, Ambry, Diagnosis, Science, NIPT, Patient, Biology, Research, Genetic distance, Chromosome, Program, ACMG, Cancer, Lists of diseases, Decision-making, Comprehensive, Health, Sex, CEO, Medical genetics, Carrier, Genetic testing, Genome, NIPS, ACOG, Child, Topical steroid withdrawal, Prenatal care, Database, CARE, Pregnancy, American College, Medical imaging, Birth control, Medicine, Genomics, Gynaecology

ACOG also recommends that carrier screening be offered to everyone in pregnancy, ideally, before pregnancy.

Key Points: 
  • ACOG also recommends that carrier screening be offered to everyone in pregnancy, ideally, before pregnancy.
  • Carrier screening helps inform a couple if they are at risk for having a child with certain genetic conditions.
  • With digital technology, we help busy physicians standardize and optimize processes so they can provide more equitable care through this reproductive health screening program.
  • The program provides comprehensive education about reproductive screening, carrier screening of reproductive partners, sensitive disclosure of test results and access to post-test counseling.

JUNO DIAGNOSTICS STRENGTHENS THE ORGANIZATION WITH APPOINTMENT OF GINA GRAYUM TO COMMERCIAL LEADERSHIP TEAM

Retrieved on: 
Tuesday, October 18, 2022
SAN, LinkedIn, Woman, Women's health, Sequenom, Phlebotomy, Patient, Collection, GenePeeks, Company, Marketing, Health, Genetic testing, NIPS, Pharmaceutical industry, Management, Invitae

SAN DIEGO, Oct. 18, 2022 /PRNewswire/ -- Juno Diagnostics (JunoDx), a company focused on bringing vital health information to patients by improving access, affordability and transparency, today announced the addition of Gina Grayum to its commercial leadership team.

Key Points: 
  • SAN DIEGO, Oct. 18, 2022 /PRNewswire/ -- Juno Diagnostics (JunoDx), a company focused on bringing vital health information to patients by improving access, affordability and transparency, today announced the addition of Gina Grayum to its commercial leadership team.
  • Ms. Grayum brings more than a decade of diagnostics sales and management experience to JunoDx, most recently as U.S.
  • "We are excited to welcome someone of Gina's caliber to the JunoDx leadership team.
  • Juno Diagnostics is a category defining health company bringing vital prenatal health information to patients by combining access, affordability and transparency.

JUNO DIAGNOSTICS ANNOUNCES APPOINTMENT OF TODD WHITSON AS EVP, GLOBAL BUSINESS DEVELOPMENT AND COMMERCIAL OPERATIONS

Retrieved on: 
Thursday, October 6, 2022
SAN, Physician, LinkedIn, Hoffmann-La Roche, Infection, Pregnancy, Patient, Phlebotomy, Urine, Nucleic acid thermodynamics, Collection, Company, Medicare, Health, Commercial Operating System (COS), Genetic testing, Genetics, NIPS, DNA, Prenatal care, Heart, Liquid biopsy, Leadership, Pharmaceutical industry, Medical imaging

SAN DIEGO, Oct. 6, 2022 /PRNewswire/ -- Juno Diagnostics (JunoDx), a company focused on bringing vital health information to patients by improving access, affordability and transparency, today announced the appointment of Todd Whitson as Executive Vice President, Global Business Development and Commercial Operations.

Key Points: 
  • SAN DIEGO, Oct. 6, 2022 /PRNewswire/ -- Juno Diagnostics (JunoDx), a company focused on bringing vital health information to patients by improving access, affordability and transparency, today announced the appointment of Todd Whitson as Executive Vice President, Global Business Development and Commercial Operations.
  • Mr. Whitson is a well-recognized veteran in the genetics and molecular diagnostics fields who brings more than two decades of healthcare experience to JunoDx.
  • "Todd is a proven commercial leader with over twenty years of experience.
  • Juno Diagnostics is a category defining health company bringing vital prenatal health information to patients by combining access, affordability and transparency.